Nanomedicine Captures Cardiovascular Disease
2008; Lippincott Williams & Wilkins; Volume: 28; Issue: 5 Linguagem: Romeno
10.1161/atvbaha.108.165332
ISSN1524-4636
AutoresWillem J. M. Mulder, Zahi A. Fayad,
Tópico(s)Cardiac and Coronary Surgery Techniques
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 28, No. 5Nanomedicine Captures Cardiovascular Disease Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBNanomedicine Captures Cardiovascular Disease Willem J.M. Mulder and Zahi A. Fayad Willem J.M. MulderWillem J.M. Mulder From the Translational and Molecular Imaging Institute and Imaging Science Laboratories, Mount Sinai School of Medicine, New York. and Zahi A. FayadZahi A. Fayad From the Translational and Molecular Imaging Institute and Imaging Science Laboratories, Mount Sinai School of Medicine, New York. Originally published1 May 2008https://doi.org/10.1161/ATVBAHA.108.165332Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:801–802Nanomedicine, the research field that makes use of nanoparticulate agents for biomedical applications, is well established in oncology.1 In fact, the application of nanotechnology in medicine started with, and is most prominently present in, targeted therapeutics for cancer. The initial goals included altering pharmacokinetics, increasing the percentage of injected dose to reach the tumor, accomplishing target-specific delivery and uptake therefore decreasing doses of compounds with antitumor activity.2 Furthermore, nanoparticles may be used to solubilize hydrophobic or amphiphilic molecules. Many nanoparticulate formulations (eg, cytostatic agents) have been shown to exhibit increased therapeutic efficacy and diminished adverse effects, which have ultimately resulted in their clinical application.3 The most well-known nanoparticulate formulations applied are liposomes (bilayered vesicles of phospholipids) which can contain a hydrophilic payload in their lumen or an amphiphilic payload in the lipid bilayer.3 Doxil, a liposomal formulation of doxorubicin, is approved for the treatment of solid tumors in patients with breast-carcinoma metastases, and has resulted in a subsequent improvement in survival.4 Gene targeting to angiogenic tumor blood vessels using cationic liposomes specific for αvβ3-intergin has shown efficacy in tumor bearing mice.5 Using this approach, apoptosis of the tumor-associated endothelium was induced by a mutant Raf gene, ultimately leading to tumor cell apoptosis and sustained regression of established primary and metastatic tumors. More recently, a synergistic approach that focuses on cutting of the blood supply of the tumor and killing tumor cells was realized using so-called nanocells, nanoparticles that contain both an angiostatic and a cytostatic drug.6See accompanying article on page 820In the late 1990's, advances in molecular biology and genetics in general and the establishment of the "molecular imaging" research field7 in particular led to a resurgent interest in nanoparticle targeting. To this aim, nanoparticles, specifically targeted to epitopes of interest, were loaded with contrast generating material to allow their detection by diagnostic imaging. The early reports primarily focused on cancer,8,9 but in the beginning of the 21st century, the first reports about the use of nanoparticles for molecular imaging of cardiovascular disease appeared.10For example, molecular MRI of macrophages in atherosclerosis has been accomplished using ultrasmall particles of iron oxide11 or paramagnetic immunomicelles.12 More recently, Hyafil et al have shown the possibility to image macrophages in atherosclerotic plaques with computed tomography imaging using N1177, a nanoparticulate formulation of iodine.13 Molecular imaging of other important features of atherosclerosis, ie, thrombus, plaque angiogenesis, and lipoproteins has also been accomplished using paramagnetic nanoparticles.14–16Several multimodality molecular imaging17 studies of cardiovascular disease related processes, including apoptosis after myocardial infarction18 and the overexpression of cell adhesion molecules in atherosclerosis,19 have been realized using superparamagnetic cross-linked iron oxide nanoparticles that were additionally labeled for fluorescence or nuclear imaging.20 These studies revealed the significance of integrating multiple properties within one nanoparticle to allow exploitation of the strengths of the different imaging modalities used. These differences may be related to sensitivity, spatial and temporal resolution, or the ability to image multiple targets simultaneously.All the aforementioned developments have revolutionized the application of nanotechnology in cardiovascular pathologies and have led to improved understanding of the possibilities for drug delivery to diseased tissue, eg, atherosclerotic plaques. In 2006 Winter et al from the Washington University School of Medicine (St Louis) reported plaque angiogenesis inhibition using paramagnetic perfluorocarbon nanoparticles that were loaded with fumagillin, while molecular imaging was used as a noninvasive read-out for therapeutic efficacy.21 This type of nanoparticle, schematically depicted in the Figure, is able to characterize and interfere in the dynamics of cardiovascular disease in a number of ways. The targeting ability and nature of its payload allows it to both "capture" and act on the specified tissue while allowing its activity to be "captured" by noninvasive imaging modalities such as MRI. Download figureDownload PowerPointFigure. Schematic representation of a target-specific nanoparticle that carries a payload of both therapeutic and MRI active materials.In the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology, a report from the same St Louis investigators demonstrates another innovative application of αvβ3-specific paramagnetic nanoparticles. After angioplasty, vascular stenosis may reoccur. This restenosis process may be inhibited by placing drug eluting stents (DES) that locally release antiproliferative agents.22 However, there are some serious limitations to DES, such as their placement and inhibited endothelial healing. Cyrus et al developed an innovative approach to locally deliver rapamycin via αvβ3-specific nanoparticles without the use of a stent. As a model, they used hyperlipidemic rabbits that underwent injury of the femoral artery using an angioplasty cathether. The injured arteries were incubated locally for a short period of time with the nanoparticles by temporarily blocking the blood flow using vascular snares. After thorough washing to remove unbound nanoparticles, the blood flow was reestablished. MRI was used to determine stenosis and, because of the paramagnetic properties included in the formulation, was also used to visualize nanoparticle delivery. Two weeks after treatment, MRI revealed the occurrence of restenosis in the femoral arteries treated with control agents, whereas the αvβ3-specific nanoparticle treated femoral arteries displayed no lumen irregularities. These in vivo findings were validated histologically and revealed significantly less atherosclerotic plaque formation in the treated arteries as compared to controls. Importantly, and in contradiction with what is normally observed after placing DES, endothelial healing occurred within 4 weeks.The study by Cyrus et al demonstrates another useful and innovative application of nanotechnology in cardiovascular disease. Although the incubation approach using vascular snares poses a limitation on the applicability, systemic exposure of rapamycin is minimized, likely diminishing serious adverse effects related to this drug. In previous studies it was demonstrated that αvβ3-specific perfluorocarbon nanoparticles also specifically target plaques after intravenous administration15 which would allow the delivery of rapamycin to vessel areas that cannot be locally incubated.The general concept of using nanoparticulate agents in cardiovascular disease has gained increasingly wider acceptance because of advances in target-specific molecular imaging. Combinatory therapy and imaging approaches are extremely useful in assessing agent delivery as well as therapeutic efficacy. Therefore, it may be anticipated that nanomedicine and noninvasive imaging will continue to contribute to improved diagnosis and treatment of atherosclerosis and cardiovascular disease in general.23Sources of FundingThis work was partly funded by the National Institutes of Health and the National Heart, Lung, and Blood Institute (NIH/NHLBI ROI HL71021, NIH/ NHLBI HL78667 to Z.A.F.).DisclosuresNone.FootnotesCorrespondence to Willem J.M. Mulder, Translational and Molecular Imaging Institute and Imaging Science Laboratories, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029. E-mail [email protected] References 1 Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007; 120: 2527–2537.CrossrefMedlineGoogle Scholar2 Allen TM, Cheng WW, Hare JI, Laginha KM. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem. 2006; 6: 513–523.CrossrefMedlineGoogle Scholar3 Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4: 145–160.CrossrefMedlineGoogle Scholar4 Perez AT, Domenech GH, Frankel C, Vogel CL. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network Inc, experience. Cancer Invest. 2002; 20: 22–29.CrossrefMedlineGoogle Scholar5 Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002; 296: 2404–2407.CrossrefMedlineGoogle Scholar6 Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005; 436: 568–572.CrossrefMedlineGoogle Scholar7 Weissleder R, Mahmood U. Molecular imaging. Radiology. 2001; 219: 316–333.CrossrefMedlineGoogle Scholar8 Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998; 4: 623–626.CrossrefMedlineGoogle Scholar9 Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP. In vivo magnetic resonance imaging of transgene expression. Nat Med. 2000; 6: 351–355.CrossrefMedlineGoogle Scholar10 Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov. 2004; 3: 913–925.CrossrefMedlineGoogle Scholar11 Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001; 103: 415–422.CrossrefMedlineGoogle Scholar12 Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JG, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, Fisher EA, Fayad ZA. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A. 2007; 104: 961–966.CrossrefMedlineGoogle Scholar13 Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, Fisher EA, Fuster V, Feldman LJ, Fayad ZA. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med. 2007; 13: 636–641.CrossrefMedlineGoogle Scholar14 Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM. Novel MRI contrast agent for molecular imaging of fibrin implications for detecting vulnerable plaques. Circulation. 2001; 104: 1280–1285.CrossrefMedlineGoogle Scholar15 Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003; 108: 2270–2274.LinkGoogle Scholar16 Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004; 126: 16316–16317.CrossrefMedlineGoogle Scholar17 Mulder WJ, Griffioen AW, Strijkers GJ, Cormode P, Nicolay K, Fayad ZA. Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine. 2007; 2: 307–324.CrossrefMedlineGoogle Scholar18 Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G, Reynolds F, Grazette L, Rosenzweig A, Weissleder R, Josephson L. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn Reson Med. 2005; 54: 718–724.CrossrefMedlineGoogle Scholar19 Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006; 114: 1504–1511.LinkGoogle Scholar20 McCarthy JR, Kelly KA, Sun EY, Weissleder R. Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine. 2007; 2: 153–167.CrossrefMedlineGoogle Scholar21 Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, Zhang H, Wickline SA, Lanza GM. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26: 2103–2109.LinkGoogle Scholar22 Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315–1323.CrossrefMedlineGoogle Scholar23 Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008; 451: 953–957.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Naima N and Zeshan H (2021) Therapeutic applications of nanozymes and their role in cardiovascular disease, International Journal of Nanomaterials, Nanotechnology and Nanomedicine, 10.17352/2455-3492.000039, (009-018), Online publication date: 18-Jan-2021. Jiang F, Zhu Y, Gong C and Wei X Atherosclerosis and Nanomedicine Potential: Current Advances and Future Opportunities, Current Medicinal Chemistry, 10.2174/0929867326666190301143952, 27:21, (3534-3554) Gajendran B, Durai P, Varier K, Liu W, Li Y, Rajendran S, Nagarathnam R and Chinnasamy A (2019) Green Synthesis of Silver Nanoparticle from Datura inoxia Flower Extract and Its Cytotoxic Activity, BioNanoScience, 10.1007/s12668-019-00645-9, 9:3, (564-572), Online publication date: 1-Sep-2019. Janakiraman V, Govindarajan K and C R M (2019) Biosynthesis of Silver Nanoparticles from Endophytic Fungi, and its Cytotoxic Activity, BioNanoScience, 10.1007/s12668-019-00631-1, 9:3, (573-579), Online publication date: 1-Sep-2019. Reddy G, Saritha K, Reddy Y and Reddy N (2019) Eco-friendly synthesis and evaluation of biological activity of silver nanoparticles from leaf extract of Indigofera barberi Gamble: an endemic plant of Seshachalam Biosphere Reserve, SN Applied Sciences, 10.1007/s42452-019-1008-0, 1:9, Online publication date: 1-Sep-2019. Netala V, Bukke S, Domdi L, Soneya S, G. Reddy S, Bethu M, Kotakdi V, Saritha K and Tartte V (2018) Biogenesis of silver nanoparticles using leaf extract of Indigofera hirsuta L. and their potential biomedical applications (3-in-1 system) , Artificial Cells, Nanomedicine, and Biotechnology, 10.1080/21691401.2018.1446967, 46:sup1, (1138-1148), Online publication date: 31-Oct-2018. Chen F, Hableel G, Zhao E and Jokerst J (2018) Multifunctional nanomedicine with silica: Role of silica in nanoparticles for theranostic, imaging, and drug monitoring, Journal of Colloid and Interface Science, 10.1016/j.jcis.2018.02.053, 521, (261-279), Online publication date: 1-Jul-2018. Mukherjee S, Nethi S and Patra C (2017) Green Synthesized Gold Nanoparticles for Future Biomedical Applications Particulate Technology for Delivery of Therapeutics, 10.1007/978-981-10-3647-7_11, (359-393), . Chen F, Ma M, Wang J, Wang F, Chern S, Zhao E, Jhunjhunwala A, Darmadi S, Chen H and Jokerst J (2017) Exosome-like silica nanoparticles: a novel ultrasound contrast agent for stem cell imaging, Nanoscale, 10.1039/C6NR08177K, 9:1, (402-411) Matoba T, Koga J, Nakano K, Egashira K and Tsutsui H (2017) Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease, Journal of Cardiology, 10.1016/j.jjcc.2017.03.005, 70:3, (206-211), Online publication date: 1-Sep-2017. Gadde S and Rayner K (2016) Nanomedicine Meets microRNA, Arteriosclerosis, Thrombosis, and Vascular Biology, 36:9, (e73-e79), Online publication date: 1-Sep-2016. Wang Y, Larsson M, Huang W, Chiou S, Nicholls S, Chao J and Liu D (2016) The use of polymer-based nanoparticles and nanostructured materials in treatment and diagnosis of cardiovascular diseases: Recent advances and emerging designs, Progress in Polymer Science, 10.1016/j.progpolymsci.2016.01.002, 57, (153-178), Online publication date: 1-Jun-2016. Bollu V, Nethi S, Dasari R, Rao S, Misra S and Patra C (2015) Evaluation of in vivo cytogenetic toxicity of europium hydroxide nanorods (EHNs) in male and female Swiss albino mice , Nanotoxicology, 10.3109/17435390.2015.1073398, 10:4, (413-425), Online publication date: 20-Apr-2016. Yao J, van Marwijk J, Wilhelmi B and Whiteley C (2015) Isolation, characterization, interaction of a thiazolekinase (Plasmodium falciparum) with silver nanoparticles, International Journal of Biological Macromolecules, 10.1016/j.ijbiomac.2015.05.033, 79, (644-653), Online publication date: 1-Aug-2015. Bhaumik J, Mittal A, Banerjee A, Chisti Y and Banerjee U (2014) Applications of phototheranostic nanoagents in photodynamic therapy, Nano Research, 10.1007/s12274-014-0628-3, 8:5, (1373-1394), Online publication date: 1-May-2015. Kunjachan S, Ehling J, Storm G, Kiessling F and Lammers T (2015) Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects, Chemical Reviews, 10.1021/cr500314d, 115:19, (10907-10937), Online publication date: 14-Oct-2015. Matoba T and Egashira K (2014) Nanoparticle-Mediated Drug Delivery System for Cardiovascular Disease, International Heart Journal, 10.1536/ihj.14-150, 55:4, (281-286), . Nethi S, Mukherjee S, Veeriah V, Barui A, Chatterjee S and Patra C (2014) Bioconjugated gold nanoparticles accelerate the growth of new blood vessels through redox signaling, Chem. Commun., 10.1039/C4CC06996J, 50:92, (14367-14370) Padayachee E, Arowolo A and Whiteley C (2013) Nanomedicine: Action of Metal Nanoparticles on Neuronal Nitric Oxide Synthase—Fluorimetric Analysis on the Mechanism for Fibrillogenesis, Neurochemical Research, 10.1007/s11064-013-1206-x, 39:1, (194-201), Online publication date: 1-Jan-2014. Meraz I, Segura-Ibarra V, Leonard F, Gonzalez J, Ally S, Godin B and Serda R (2013) Biological Microniches Characterizing Pathological Lesions Nanomedicine, 10.1016/B978-0-08-098338-7.00006-6, (139-173), . Zhang H, Li N, Sirish P, Mahakian L, Ingham E, Curry F, Yamada S, Chiamvimonvat N and Ferrara K (2012) The cargo of CRPPR-conjugated liposomes crosses the intact murine cardiac endothelium, Journal of Controlled Release, 10.1016/j.jconrel.2012.06.038, 163:1, (10-17), Online publication date: 1-Oct-2012. Sennuga A, van Marwijk J, Boshoff A and Whiteley C (2012) Enhanced activity of chaperonin GroEL in the presence of platinum nanoparticles, Journal of Nanoparticle Research, 10.1007/s11051-012-0824-6, 14:5, Online publication date: 1-May-2012. Fayad Z (2011) Targeted MRI of Molecular Components in Atherosclerotic Plaque Asymptomatic Atherosclerosis, 10.1007/978-1-60327-179-0_31, (429-432), . Valencia P, Hanewich-Hollatz M, Gao W, Karim F, Langer R, Karnik R and Farokhzad O (2011) Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles, Biomaterials, 10.1016/j.biomaterials.2011.04.078, 32:26, (6226-6233), Online publication date: 1-Sep-2011. Roy R, Roy B and Sengupta S (2011) Emerging technologies for enabling proangiogenic therapy, Nanotechnology, 10.1088/0957-4484/22/49/494004, 22:49, (494004), Online publication date: 9-Dec-2011. Feig J, Pineda-Torra I, Sanson M, Bradley M, Vengrenyuk Y, Bogunovic D, Gautier E, Rubinstein D, Hong C, Liu J, Wu C, van Rooijen N, Bhardwaj N, Garabedian M, Tontonoz P and Fisher E (2010) LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression, Journal of Clinical Investigation, 10.1172/JCI38911, 120:12, (4415-4424), Online publication date: 1-Dec-2010. Khan T, Vohra R and Homer-Vanniasinkam S (2010) Nanotechnology and nanomedicine in cardiovascular therapy Biomaterials and Devices for the Circulatory System, 10.1533/9780857090553.3.251, (251-269), . Yathindranath V, Hegmann T, van Lierop J, Potter K, Fowler C and Moore D (2009) Simultaneous magnetically directed drug convection and MR imaging, Nanotechnology, 10.1088/0957-4484/20/40/405101, 20:40, (405101), Online publication date: 7-Oct-2009. Sun Y, Chen L, Zhao S, Shi L, Li H, Tian W and Qi G (2020) Effects of nanoparticle‑mediated delivery of pitavastatin on atherosclerotic plaques in ApoE‑knockout mice and THP‑1‑derived macrophages, Experimental and Therapeutic Medicine, 10.3892/etm.2020.8632 Manners N, Priya V, Mehata A, Rawat M, Mohan S, Makeen H, Albratty M, Albarrati A, Meraya A and Muthu M (2022) Theranostic Nanomedicines for the Treatment of Cardiovascular and Related Diseases: Current Strategies and Future Perspectives, Pharmaceuticals, 10.3390/ph15040441, 15:4, (441) May 2008Vol 28, Issue 5 Advertisement Article InformationMetrics https://doi.org/10.1161/ATVBAHA.108.165332PMID: 18421003 Originally publishedMay 1, 2008 PDF download Advertisement
Referência(s)